TAK – Takeda Pharmaceutical | Premier Stocks League

TAK Takeda Pharmaceutical

Official Name: Takeda Pharmaceutical Company Limited
Headquarters: 75 Sidney Street Cambridge, MASSACHUSETTS 02139, US
CEO: Christophe Weber
Website: takeda.com

Match Results

Date	League	Week	Opponent	Result	Score
2025-07-15	INV C	1R	HWC	Won by 0.412	(2.652) - (3.064)
2025-07-18	N-L 2	1	COLL	Won by 5.310	2.678 - (2.632)
2025-07-25	N-L 2	2	INDB	Won by 4.627	3.459 - (1.168)
2025-07-29	INV C	2R	PTC	Lost by 0.071	0.585 - 0.656
2025-08-01	N-L 2	3	GOLF	Won by 15.735	9.652 - (6.083)
2025-08-08	N-L 2	4	SLF	Won by 9.104	5.092 - (4.012)
2025-08-15	N-L 2	5	TTGT	Won by 3.917	3.917 - 0.000
2025-08-22	N-L 2	6	SAM	Won by 1.498	3.094 - 1.596
2025-08-29	N-L 2	7	SLF	Lost by 2.731	(3.609) - (0.878)
2025-09-05	N-L 2	8	SLF	Won by 4.622	3.384 - (1.238)
2025-09-12	N-L 2	9	SAM	Won by 2.644	(2.312) - (4.956)
2025-09-19	N-L 2	10	SLF	Lost by 2.276	(0.274) - 2.002
2025-09-26	N-L 2	11	SLF	Lost by 0.354	(2.378) - (2.024)
2025-10-03	N-L 2	12	SLF	Lost by 3.937	(0.874) - 3.063
2025-10-10	N-L 2	13	SAM	Lost by 0.976	(6.000) - (5.024)
2025-10-17	N-L 2	14	SAM	Lost by 1.468	2.612 - 4.080
2025-10-24	N-L 2	15	COLL	Lost by 4.452	(0.228) - 4.224

Latest News

Yahoo - 2026-10-15

Cathie Wood-Backed Biotech IPO Pops in Debut 🔗

The IPO market may be in a bit of a slump as investors wait for Anthropic to finally file officially for a stock sale.

Yahoo - 2026-10-15

Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading 🔗

Asian equities traded in the US as American depositary receipts were tracking lower Thursday morning

Benzinga - 2026-10-14

Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling 🔗

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administratio...

Yahoo - 2026-10-14

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 🔗

OSAKA, Japan & CAMBRIDGE, Mass., October 15, 2026--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japa...

Yahoo - 2026-10-14

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 🔗

OSAKA, Japan & CAMBRIDGE, Mass., October 14, 2026--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing ...

Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline

SeekingAlpha - 2026-10-13

Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative 🔗

Yahoo - 2026-09-30

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill 🔗

Benzinga - 2026-09-29

Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis 🔗

Yahoo - 2026-09-29

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD 🔗

Yahoo - 2026-09-29

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium 🔗

Benzinga - 2026-09-29

Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial 🔗

Yahoo - 2026-09-27

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC 🔗

Yahoo - 2026-09-25

Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry 🔗

SeekingAlpha - 2026-09-24

AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions 🔗

Yahoo - 2026-09-22

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 🔗

Benzinga - 2026-09-21

Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development 🔗

Yahoo - 2026-09-18

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects? 🔗

SeekingAlpha - 2026-09-18

5 Undervalued Oncology Stocks Wall Street Is Overlooking 🔗

Yahoo - 2026-09-18

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems 🔗

Yahoo - 2026-09-17

Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight 🔗

Yahoo - 2026-09-15

Hummingbird Bioscience Appoints Dr. James Garner as President 🔗

SeekingAlpha - 2026-09-14

Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 🔗

Yahoo - 2026-09-14

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations 🔗

Benzinga - 2026-09-13

Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE PsO Studies Of Nearly 3,000 Patients 🔗

SeekingAlpha - 2026-09-11

BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity 🔗

Yahoo - 2026-09-10

Andy Plump, architect of Takeda’s R&D overhaul, to retire next year 🔗

Yahoo - 2026-09-09

Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026 🔗

Yahoo - 2026-09-09

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life 🔗

Yahoo - 2026-09-09

Onco360® Has Been Selected as Part of an Ultra-Narrow Specialty Pharmacy Network for MIMRYLO™ (rusfertide) 🔗

Benzinga - 2026-09-09

Takeda's Phase 3 Trial Of Oveporexton's Data Published In New England Journal Of Medicine To Treat Narcolepsy Type 1; Oveporexton Generally Well-Tolerated With Consistent Safety Profile 🔗

Yahoo - 2026-09-08

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB 🔗

Yahoo - 2026-09-02

Takeda and Weave Bio collaborate on AI-driven automation in drug development 🔗

Yahoo - 2026-09-01

Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story? 🔗

Yahoo - 2026-09-01

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities 🔗

Yahoo - 2026-09-01

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera 🔗

Yahoo - 2026-08-28

NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open 🔗

Yahoo - 2026-08-28

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season 🔗

Yahoo - 2026-08-26

Pure Strategies Announces "Day of Action" Full Day Program during Climate Week NYC - September 23, 2026 🔗

Yahoo - 2026-08-24

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak 🔗

Yahoo - 2026-08-24

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 🔗

Benzinga - 2026-08-23

Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms 🔗

Yahoo - 2026-08-21

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 🔗

Benzinga - 2026-08-05

Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling 🔗

Yahoo - 2026-08-05

Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial 🔗

SeekingAlpha - 2026-07-30

Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript 🔗

Yahoo - 2026-07-30

Takeda Pharmaceutical Q1 Earnings Call Highlights 🔗

Benzinga - 2026-07-30

CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est 🔗

Yahoo - 2026-07-30

Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance 🔗

Yahoo - 2026-07-16

Change in Siegfried's Management Team 🔗

Yahoo - 2026-07-16

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies 🔗

Benzinga - 2026-07-16

Reported Sunday, Takeda To Invest Up To $30M In Indonesia Plasma Ecosystem As Part Of Landmark Healthcare Collaboration With Indonesian Government, Including National Plasma Donation Network Pilot 🔗

Yahoo - 2026-07-12

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products 🔗

SeekingAlpha - 2026-07-08

Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis 🔗

Benzinga - 2026-06-12

Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis Patients 🔗

Benzinga - 2026-06-09

Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion 🔗

SeekingAlpha - 2026-05-18

Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo 🔗

SeekingAlpha - 2026-05-13

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results 🔗

Benzinga - 2026-05-13

Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality 🔗

Yahoo - 2026-05-05

British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome 🔗

Yahoo - 2026-05-04

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) 🔗

Benzinga - 2026-05-04

Takeda Announces That The TAK-881-300 Phase 2/3 Clinical Trial In Patients With Primary Immunodeficiency Disease 1 Met Its Primary Endpoint, 🔗

Yahoo - 2026-05-04

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease 🔗

Yahoo - 2026-04-29

Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda Pharma 🔗

Yahoo - 2026-04-27

Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying. 🔗

Yahoo - 2026-04-24

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? 🔗

Yahoo - 2026-04-24

Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics 🔗

Yahoo - 2026-04-23

SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally? 🔗

Yahoo - 2026-04-23

Kawasaki Disease Market Analysis and Global Forecast Report 2025-2035 Featuring Prominent Players - Takeda Pharmaceutical, CSL Behring, Grifols, ADMA Biologics, and Octapharma 🔗

Yahoo - 2026-04-23